Scholarlink

<p>Statins are a cornerstone of cardiovascular risk reduction. Nevertheless, non-acceptance of statin therapy recommendations by patients at high cardiovascular risk is common. The reasons for statin non-acceptance have not been well established. We conducted a manual record review of a randomly selected set of patients who did not accept statin therapy recommendations to identify (a) documented reasons for statin non-acceptance and (b) patients’ demographic characteristics, comorbidities and current treatment. We analyzed the relationships between patients’ characteristics and reasons for statin non-acceptance. The most common reasons for statin non-acceptance were preference for lifestyle modifications (51.5%), general aversion to medications (19.1%), polypharmacy burden (17.1%) and fear of adverse reactions (10.9%). Patients taking more medications were more likely to express a concern about polypharmacy burden (OR 1.09; 95% CI 1.005–1.18). Patients who previously had adverse reactions to non-cholesterol lowering medications were more likely to fear adverse reactions to statins (OR 1.13; 95% CI 1.001–1.28). Patients who expressed preference for lifestyle modifications had time to low density lipoprotein cholesterol (LDL-C) &lt; 100&#xa0;mg/dL similar to patients who did not accept statin therapy for other reasons (1935 vs. 1777&#xa0;days, <i>p</i> = 0.26). Patients’ reasons for non-acceptance of statin therapy are often linked to their past and present medical experience. Appropriately addressing these concerns is important to maximizing cardiovascular risk reduction in individuals who may be reluctant to initiate statin therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Reasons for non-acceptance of statin therapy by patients at high cardiovascular risk

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月16日

查看全文
  • Minjia Xie,
  • Seth S. Martin,
  • Alexander Turchin

摘要

Statins are a cornerstone of cardiovascular risk reduction. Nevertheless, non-acceptance of statin therapy recommendations by patients at high cardiovascular risk is common. The reasons for statin non-acceptance have not been well established. We conducted a manual record review of a randomly selected set of patients who did not accept statin therapy recommendations to identify (a) documented reasons for statin non-acceptance and (b) patients’ demographic characteristics, comorbidities and current treatment. We analyzed the relationships between patients’ characteristics and reasons for statin non-acceptance. The most common reasons for statin non-acceptance were preference for lifestyle modifications (51.5%), general aversion to medications (19.1%), polypharmacy burden (17.1%) and fear of adverse reactions (10.9%). Patients taking more medications were more likely to express a concern about polypharmacy burden (OR 1.09; 95% CI 1.005–1.18). Patients who previously had adverse reactions to non-cholesterol lowering medications were more likely to fear adverse reactions to statins (OR 1.13; 95% CI 1.001–1.28). Patients who expressed preference for lifestyle modifications had time to low density lipoprotein cholesterol (LDL-C) < 100 mg/dL similar to patients who did not accept statin therapy for other reasons (1935 vs. 1777 days, p = 0.26). Patients’ reasons for non-acceptance of statin therapy are often linked to their past and present medical experience. Appropriately addressing these concerns is important to maximizing cardiovascular risk reduction in individuals who may be reluctant to initiate statin therapy.